{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:08:02Z","timestamp":1790226482942,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.amjcard.2016.09.019","type":"journal-article","created":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:08:39Z","timestamp":1475366919000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population"],"prefix":"10.1016","volume":"119","author":[{"given":"Tasnim F.","family":"Imran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njambi","family":"Mathenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Gaziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Djouss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.09.019_bib1","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics\u20132013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.09.019_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.amjcard.2016.09.019_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s003359900548","article-title":"Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22","volume":"8","author":"Raimond","year":"1997","journal-title":"Mamm Genome"},{"key":"10.1016\/j.amjcard.2016.09.019_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pre-brain natriuretic peptide, galectin-3 and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","article-title":"Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure","volume":"102","author":"Lok","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2015.02.008","article-title":"Galectin-3 and myocardial fibrosis in non-ischemic dilated cardiomyopathy","volume":"184","author":"Vergaro","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2012.08.021","article-title":"The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"164","author":"Gullestad","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2016.09.019_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.05.040","article-title":"Predictive value of galecin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort","volume":"192","author":"Jagodinzki","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib10","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses. In 2013. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed February 5, 2016."},{"key":"10.1016\/j.amjcard.2016.09.019_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2011.174359","article-title":"Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22","volume":"58","author":"Grandin","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjcard.2016.09.019_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2013.08.081","article-title":"Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction","volume":"169","author":"Carrasco-Sanchez","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib13","article-title":"Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis","volume":"3","author":"Madrigal-Matute","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2016.09.019_bib14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.21","article-title":"Plasma galectin 3 and heart failure risk in the Physicians' Health Study","volume":"16","author":"Djousse","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.09.019_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to meta-analysis","volume":"135","author":"Greenland","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.amjcard.2016.09.019_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-2 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijcard.2011.05.081","article-title":"Galectin-3 in heart failure: high levels are associated with all-cause mortality","volume":"150","author":"Ueland","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","article-title":"Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-Heft","volume":"15","author":"Anand","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2016.09.019_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2016.09.019_bib22","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1681\/ASN.2014010093","article-title":"Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies","volume":"26","author":"Drechsler","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrsc.2015.08.002","article-title":"Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: the ADVANCE study","volume":"5","author":"Iribarren","year":"2015","journal-title":"Clin Trials Regul Sci Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cardfail.2014.10.006","article-title":"The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure","volume":"21","author":"Zhang","year":"2015","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.amjcard.2016.09.019_bib26","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2014.12.137","article-title":"Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis","volume":"182","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.019_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491631579X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291491631579X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:50:38Z","timestamp":1536367838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291491631579X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S000291491631579X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.09.019","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}